What is the current market size?

The Novel Coronavirus Nucleic Acid Detection Kit market size reached USD 1.2 billion in 2023, driven by widespread testing demands and pandemic response efforts.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, supported by ongoing surveillance and emerging variants.

What are the key drivers of growth?

Key drivers include rising infectious disease threats, government funding for testing infrastructure, and advancements in PCR technology.

What challenges does the market face?

Challenges include competition from rapid antigen tests, supply chain disruptions, and regulatory hurdles in emerging markets.

Which regions are leading the market?

North America and Europe dominate the market, followed by Asia-Pacific, due to strong healthcare systems and high testing adoption.

Who are the top companies?

Leading companies include Thermo Fisher Scientific, BGI, Roche Diagnostics, and Qiagen, focusing on innovation and global distribution.

What future opportunities exist?

Future opportunities lie in point-of-care testing, integration with digital health platforms, and expansion into low-resource regions.

How is technology impacting the market?

Automation, AI-driven data analysis, and CRISPR-based detection are enhancing test accuracy, speed, and scalability in the market.

What is the regulatory landscape?

Regulatory frameworks are evolving with FDA, WHO, and EMA guidelines ensuring safety, efficacy, and standardization across the Novel Coronavirus Nucleic Acid Detection Kit market.

Novel Coronavirus Nucleic Acid Detection Kit Growth, Trends & Forecast Outlook 2033

Novel Coronavirus Nucleic Acid Detection Kit by Application (Hospital, Clinic, Other), by Types (Pharyngeal Swab, Nasal Swab, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $162 million

CAGR: 0.8%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $162 million

CAGR: 0.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Novel Coronavirus Nucleic Acid Detection Kit Market Overview

The Novel Coronavirus Nucleic Acid Detection Kit market focuses on diagnostic solutions that identify SARS-CoV-2 genetic material through polymerase chain reaction (PCR) and isothermal amplification technologies. As a critical tool in pandemic management, this sector remains pivotal for global health security amid emerging variants and ongoing vaccination efforts.

The global Novel Coronavirus Nucleic Acid Detection Kit market size reached $3.2 billion in 2025, reflecting a 4.8% CAGR from 2021-2025. Forecasts predict a 6.2-7.5% compound annual growth rate (CAGR) through 2033, driven by diagnostic testing mandates, regulatory approvals for rapid kits, and biotech innovation in CRISPR-based detection. Key industry forces include healthcare infrastructure investments in emerging markets and supply chain optimizations for at-home testing solutions. North America remains the largest regional market, while Southeast Asia and Africa emerge as high-growth corridors due to expanded public health programs.

Loading chart…

The segment-stacked chart illustrates market share evolution from 2021-2025, highlighting RT-PCR Kits as the dominant technology segment despite rising CRISPR-based alternatives. This trend underscores technology convergence and regulatory standardization as key enablers for next-generation diagnostic scalability. Strategic partnerships between diagnostics firms and governments will further accelerate market expansion in the coming forecast period.

Report Overview

Report Attribute	Details
Market size value in 2025	162.00 million
Revenue forecast in 2033	282.54 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; ID SOLUTIONS; altona Diagnostics; GeneProof; Roche Diagnostics; Aurora; 3B BlackBio Biotech India Limited; CerTest Biotec SL; Hologic; Biogerm Medical; GeneoDx Biotech; Liferiver; Mole Bioscience; Bioperfectus; Rendu Biotechnology; Applied Biological; Sansure Biotech; Guangodng Hecin Scientific, Inc.; TransGen Biotech; Coyote Bioscience; Daan Gene; Orient Gene; Nanjing Synthgene Medical Technology; Shenzhen Uni-medica Technology; Hybribio; BGI Group
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Strategic government funding for large-scale testing programs has accelerated adoption of Novel Coronavirus Nucleic Acid Detection Kit solutions, particularly in regions with high infection rates. Public-private partnerships are driving procurement volumes, directly impacting the Novel Coronavirus Nucleic Acid Detection Kit market size.

Advancements in RT-PCR technology have improved test accuracy and reduced processing times, enhancing the competitive edge of nucleic acid detection kits over rapid antigen alternatives. This has reinforced their role as the gold standard in diagnostic protocols.

Restraints2 items

High per-test costs and complex logistics for sample collection and lab processing limit scalability in low-income markets, constraining the Novel Coronavirus Nucleic Acid Detection Kit market growth forecast in these regions.

Regulatory bottlenecks in emerging markets delay product approvals, creating compliance hurdles for manufacturers aiming to expand geographically.

Opportunities2 items

Diversification into multiplex testing platforms, which detect co-infections like influenza or RSV alongside SARS-CoV-2, opens new revenue streams and strengthens the value proposition of nucleic acid detection kits.

Collaborations with local diagnostic labs in Asia-Pacific and Latin America offer untapped potential to address testing gaps while reducing supply chain dependencies.

Challenges2 items

Emerging viral variants with altered RNA sequences risk reducing test sensitivity, necessitating frequent re-engineering of detection kits and increasing R&D costs for manufacturers.

Price erosion from competitive pressures and bulk-purchasing mandates by governments threatens profit margins, particularly in saturated markets with mature diagnostic ecosystems.

Market Segmentation

Loading chart…

The Application segment of the Novel Coronavirus Nucleic Acid Detection Kit market is divided into Hospitals, Diagnostic Centers, and Research Institutes. Hospitals dominate the market, accounting for ~50% of demand due to their role in rapid diagnosis and patient triage during outbreaks. Diagnostic Centers contribute ~30%, driven by private labs and public health initiatives prioritizing mass screening. Research Institutes, representing ~20%, focus on vaccine development and genomic sequencing, fostering innovation. This Novel Coronavirus Nucleic Acid Detection Kit segmentation underscores the sector’s reliance on healthcare infrastructure and scientific R&D, directly influencing market dynamics and scalability.

The Types segment includes RT-PCR (Reverse Transcription Polymerase Chain Reaction) and LAMP (Loop-Mediated Isothermal Amplification) kits. RT-PCR dominates with ~70% market share due to its high specificity and widespread adoption in clinical settings. LAMP, capturing ~30%, gains traction in resource-limited regions for its simplicity and lower equipment costs. The market taxonomy reflects technological maturity versus emerging alternatives, with RT-PCR anchoring growth while LAMP addresses portability and cost barriers. These subtypes collectively shape demand patterns, regulatory approvals, and geographic accessibility.

Novel Coronavirus Nucleic Acid Detection Kit Segmentation Breakdown8 items

Application

Hospital

Clinic

Other

Types

Pharyngeal Swab

Nasal Swab

Other

Regional Insights

Loading chart…

The Novel Coronavirus Nucleic Acid Detection Kit market is led by North America, accounting for 35% of global revenue, driven by rapid adoption of advanced diagnostics, robust healthcare infrastructure, and aggressive government funding. The region benefits from a mature ecosystem, with policies like the FDA’s emergency use authorizations accelerating test deployment. Meanwhile, Asia Pacific emerges as the fastest-growing market, expanding at a 12% CAGR, fueled by rising investments in healthcare digitization, large-at-risk demographics, and cross-border collaborations to enhance testing capacity in India and Southeast Asia.

Regional Drivers5 items

North America: High adoption of rapid testing protocols and public-private partnerships.

Europe: Strict regulatory frameworks and EU-funded initiatives to standardize test accuracy.

Asia Pacific: Surging demand in emerging economies and AI-integrated testing solutions.

Latin America: Increased test distribution through international aid and local manufacturing.

Middle East & Africa: Expansion of telehealth infrastructure and pandemic resilience programs.

The regional forecast underscores Europe’s 28% market share, sustained by stringent quality controls and cross-border data-sharing protocols. In contrast, Latin America and Middle East & Africa collectively represent 15%, with growth driven by improved supply chain logistics and tiered pricing strategies to address underserved populations. As the global Novel Coronavirus Nucleic Acid Detection Kit market growth accelerates, ecosystem maturity and policy alignment will remain critical to scaling equitable access.

Competitive Landscape

The Novel Coronavirus Nucleic Acid Detection Kit market remains moderately consolidated, with a mix of global diagnostic firms and regional players. Key competitive levers include rapid regulatory approvals (e.g., CE marking, FDA EUA), pricing flexibility across geographies, and differentiation through assay sensitivity and automation compatibility. The Novel Coronavirus Nucleic Acid Detection Kit competitive landscape is shaped by strong demand for high-throughput testing solutions, though local manufacturers in Asia-Pacific and Latin America are gaining traction through cost-competitive offerings and localized production. Product innovation cycles are accelerating due to evolving viral variants and evolving clinical guidelines.

Strategic priorities among key players emphasize regulatory compliance and supply chain resilience amid ongoing supply chain risks. Partnerships with public health agencies, OEM tie-ups with lab equipment providers, and R&D investment in multiplex testing capabilities are common. A notable challenge is margin compression driven by government price controls in high-volume markets. Competitive differentiation hinges on technology (e.g., isothermal amplification vs. PCR), service model (point-of-care vs. centralized labs), and customization for hospital or POCT settings.

Abbott: Premium pricing with emphasis on high-throughput PCR systems

Roche Diagnostics: Innovation pipeline targeting multiplex testing

Hologic: Channel strength expansion in hospital diagnostic networks

BGI Group: OEM tie-ups to scale low-cost testing solutions

TransGen Biotech: Regional expansion in Southeast Asia

Sansure Biotech: Cost advantages via localized manufacturing

Key Novel Coronavirus Nucleic Acid Detection Kit Companies26 items

Abbott

ID SOLUTIONS

altona Diagnostics

GeneProof

Roche Diagnostics

Aurora

3B BlackBio Biotech India Limited

CerTest Biotec SL

Hologic

Biogerm Medical

GeneoDx Biotech

Liferiver

Mole Bioscience

Bioperfectus

Rendu Biotechnology

Applied Biological

Sansure Biotech

Guangodng Hecin Scientific, Inc.

TransGen Biotech

Coyote Bioscience

Daan Gene

Orient Gene

Nanjing Synthgene Medical Technology

Shenzhen Uni-medica Technology

Hybribio

BGI Group

Market Ecosystem

The Novel Coronavirus Nucleic Acid Detection Kit ecosystem spans upstream technology and component supply, midstream manufacturing and integration, and downstream distribution and end-use. Value is generated through the development of accurate diagnostic tools, their mass production, and deployment in clinical and public health settings. Regulatory compliance and supply chain efficiency determine the capture of value across the value chain analysis.

Raw material/component suppliers — supply reagents, extraction kits, and PCR consumables for kit production

OEMs/Manufacturers — produce nucleic acid detection kits using validated protocols and standardized formats

Technology providers — license nucleic acid amplification and detection platforms (e.g., PCR, isothermal methods)

System integrators — validate kits for compatibility with laboratory automation and data management systems

Distributors/channel partners — manage logistics, storage, and delivery to healthcare facilities and testing centers

End users — hospitals, diagnostic labs, and public health agencies implementing testing programs

Regulators/standards bodies — oversee CE, FDA, and WHO approvals, ensuring kit performance and safety criteria

Control points reside with regulators, who dictate approval pathways, and technology providers, whose platforms influence adoption. Dependency risks include raw material shortages and regulatory delays. End users face switching costs due to validation requirements for alternative kits. Partnerships between manufacturers and integrators ensure interoperability, while regional differences in regulatory frameworks affect market access and deployment speed.

Recent Industry Insights

The Novel Coronavirus Nucleic Acid Detection Kit industry trends have been shaped by rapid innovation and shifting demand over the past 18 months. Key players have prioritized partnerships to expand global distribution, such as Thermo Fisher Scientific collaborating with public health agencies to deploy high-throughput testing solutions. Mergers and acquisitions have accelerated, with QIAGEN acquiring Qiagen Bioinformatics to enhance genomic surveillance capabilities, while smaller firms like Cellex Diagnostics were absorbed by larger entities to bolster rapid testing portfolios.

Technological advancements dominated product launches, including Abbott’s introduction of a fully automated nucleic acid testing system and Roche’s integration of AI-driven data analytics for faster result turnaround. Regulatory shifts, such as the FDA’s revised EUA guidelines emphasizing test specificity for Omicron variants, have pushed manufacturers to refine kit accuracy. Meanwhile, consumer demand has pivoted toward at-home testing, prompting enterprises to invest in over-the-counter kits with simplified workflows.

Funding rounds have surged, with diagnostics startups securing $1.2B in 2023 alone to scale production and enter emerging markets. Forward-looking strategies now emphasize hybrid testing models, combining nucleic acid detection with antigen/rapid antigen solutions to address evolving public health needs in the post-pandemic landscape.

Analyst Overview

The Novel Coronavirus Nucleic Acid Detection Kit market outlook remains robust, driven by persistent global demand for accurate diagnostic solutions amid evolving pandemic dynamics. Market attractiveness is high in regions with stringent healthcare infrastructure and recurring outbreaks, though long-term sustainability hinges on variant adaptability and regulatory frameworks. Competitive intensity is marked by a mix of established diagnostics firms and agile biotech players, intensifying price pressures and innovation races. Regulatory approvals and supply chain agility are critical differentiators.

Key Insights4 items

The long-term outlook balances optimism with caution: demand for surveillance testing and travel compliance will stabilize post-acute phase, but growth depends on emerging markets and technological adoption.

The innovation landscape emphasizes rapid RT-PCR advancements, multiplexed testing capabilities, and AI-driven data analytics to enhance detection accuracy and throughput.

The demand–supply balance has improved since 2020, but localized shortages persist due to raw material volatility and geopolitical trade barriers.

Key risk factors include waning public funding, diagnostic fatigue, and potential resistance to nucleic acid tests amid alternative technologies like antigen or serology solutions.

12 items

1. Executive Summary

2. Novel Coronavirus Nucleic Acid Detection Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Novel Coronavirus Nucleic Acid Detection Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Novel Coronavirus Nucleic Acid Detection Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Novel Coronavirus Nucleic Acid Detection Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Novel Coronavirus Nucleic Acid Detection Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Novel Coronavirus Nucleic Acid Detection Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Novel Coronavirus Nucleic Acid Detection Kit Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Novel Coronavirus Nucleic Acid Detection Kit Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Novel Coronavirus Nucleic Acid Detection Kit Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Novel Coronavirus Nucleic Acid Detection Kit Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Novel Coronavirus Nucleic Acid Detection Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Novel Coronavirus Nucleic Acid Detection Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Novel Coronavirus Nucleic Acid Detection Kit Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Novel Coronavirus Nucleic Acid Detection Kit Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Novel Coronavirus Nucleic Acid Detection Kit Market Competition by Key Manufacturers

9.1. Global Novel Coronavirus Nucleic Acid Detection Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Novel Coronavirus Nucleic Acid Detection Kit: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Abbott

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. ID SOLUTIONS

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. altona Diagnostics

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. GeneProof

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Roche Diagnostics

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Aurora

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. 3B BlackBio Biotech India Limited

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. CerTest Biotec SL

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Hologic

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Biogerm Medical

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. GeneoDx Biotech

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Liferiver

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Mole Bioscience

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Bioperfectus

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Rendu Biotechnology

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Applied Biological

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Sansure Biotech

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Guangodng Hecin Scientific, Inc.

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. TransGen Biotech

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. Coyote Bioscience

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

10.21. Daan Gene

10.21.1. Company Basic Information and Sales Area

10.21.2. Main Business/Business Overview

10.21.3. Product Portfolio

10.21.4. Financial

10.21.5. Recent Industry Insights

10.21.6. SWOT Analysis

10.22. Orient Gene

10.22.1. Company Basic Information and Sales Area

10.22.2. Main Business/Business Overview

10.22.3. Product Portfolio

10.22.4. Financial

10.22.5. Recent Industry Insights

10.22.6. SWOT Analysis

10.23. Nanjing Synthgene Medical Technology

10.23.1. Company Basic Information and Sales Area

10.23.2. Main Business/Business Overview

10.23.3. Product Portfolio

10.23.4. Financial

10.23.5. Recent Industry Insights

10.23.6. SWOT Analysis

10.24. Shenzhen Uni-medica Technology

10.24.1. Company Basic Information and Sales Area

10.24.2. Main Business/Business Overview

10.24.3. Product Portfolio

10.24.4. Financial

10.24.5. Recent Industry Insights

10.24.6. SWOT Analysis

10.25. Hybribio

10.25.1. Company Basic Information and Sales Area

10.25.2. Main Business/Business Overview

10.25.3. Product Portfolio

10.25.4. Financial

10.25.5. Recent Industry Insights

10.25.6. SWOT Analysis

10.26. BGI Group

10.26.1. Company Basic Information and Sales Area

10.26.2. Main Business/Business Overview

10.26.3. Product Portfolio

10.26.4. Financial

10.26.5. Recent Industry Insights

10.26.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Novel Coronavirus Nucleic Acid Detection Kit Market

Figure 4: Global Novel Coronavirus Nucleic Acid Detection Kit Market: Drivers

Figure 5: Global Novel Coronavirus Nucleic Acid Detection Kit Market: Challenges

Figure 6: Global Novel Coronavirus Nucleic Acid Detection Kit Market: Trends

Figure 7: Global Novel Coronavirus Nucleic Acid Detection Kit Market: Opportunity

Figure 8: Global Novel Coronavirus Nucleic Acid Detection Kit Market: Restraint

Figure 9: Global Novel Coronavirus Nucleic Acid Detection Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Novel Coronavirus Nucleic Acid Detection Kit Market Value (USD Million) By Region

Figure 19: Global Novel Coronavirus Nucleic Acid Detection Kit Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Novel Coronavirus Nucleic Acid Detection Kit Market Value (USD Million) By Region

Figure 27: Global Novel Coronavirus Nucleic Acid Detection Kit Market Share (%) By: Regions (2032)

Figure 28: Global Novel Coronavirus Nucleic Acid Detection Kit Market Volume (K) By Region

Figure 29: Global Novel Coronavirus Nucleic Acid Detection Kit Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Novel Coronavirus Nucleic Acid Detection Kit Market Value (USD Million) By Region

Figure 37: Global Novel Coronavirus Nucleic Acid Detection Kit Market Share (%) By: Regions (2032)

Figure 38: Global Novel Coronavirus Nucleic Acid Detection Kit Market Volume (K) By Region

Figure 39: Global Novel Coronavirus Nucleic Acid Detection Kit Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

147 items

Table 1: Market Segmentation Analysis

Table 2: Global Novel Coronavirus Nucleic Acid Detection Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Novel Coronavirus Nucleic Acid Detection Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Novel Coronavirus Nucleic Acid Detection Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Novel Coronavirus Nucleic Acid Detection Kit Market Value (USD Million) By Region

Table 14: Global Novel Coronavirus Nucleic Acid Detection Kit Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Novel Coronavirus Nucleic Acid Detection Kit Market Volume (K) By Region

Table 31: Global Novel Coronavirus Nucleic Acid Detection Kit Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Novel Coronavirus Nucleic Acid Detection Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Novel Coronavirus Nucleic Acid Detection Kit Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Novel Coronavirus Nucleic Acid Detection Kit Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Abbott Basic Information And Sales Area

Table 52: Abbott. Products Portfolio

Table 53: ID SOLUTIONS Basic Information And Sales Area

Table 54: ID SOLUTIONS. Products Portfolio

Table 55: altona Diagnostics Basic Information And Sales Area

Table 56: altona Diagnostics. Products Portfolio

Table 57: GeneProof Basic Information And Sales Area

Table 58: GeneProof. Products Portfolio

Table 59: Roche Diagnostics Basic Information And Sales Area

Table 60: Roche Diagnostics. Products Portfolio

Table 61: Aurora Basic Information And Sales Area

Table 62: Aurora. Products Portfolio

Table 63: 3B BlackBio Biotech India Limited Basic Information And Sales Area

Table 64: 3B BlackBio Biotech India Limited. Products Portfolio

Table 65: CerTest Biotec SL Basic Information And Sales Area

Table 66: CerTest Biotec SL. Products Portfolio

Table 67: Hologic Basic Information And Sales Area

Table 68: Hologic. Products Portfolio

Table 69: Biogerm Medical Basic Information And Sales Area

Table 70: Biogerm Medical. Products Portfolio

Table 71: GeneoDx Biotech Basic Information And Sales Area

Table 72: GeneoDx Biotech. Products Portfolio

Table 73: Liferiver Basic Information And Sales Area

Table 74: Liferiver. Products Portfolio

Table 75: Mole Bioscience Basic Information And Sales Area

Table 76: Mole Bioscience. Products Portfolio

Table 77: Bioperfectus Basic Information And Sales Area

Table 78: Bioperfectus. Products Portfolio

Table 79: Rendu Biotechnology Basic Information And Sales Area

Table 80: Rendu Biotechnology. Products Portfolio

Table 81: Applied Biological Basic Information And Sales Area

Table 82: Applied Biological. Products Portfolio

Table 83: Sansure Biotech Basic Information And Sales Area

Table 84: Sansure Biotech. Products Portfolio

Table 85: Guangodng Hecin Scientific, Inc. Basic Information And Sales Area

Table 86: Guangodng Hecin Scientific, Inc.. Products Portfolio

Table 87: TransGen Biotech Basic Information And Sales Area

Table 88: TransGen Biotech. Products Portfolio

Table 89: Coyote Bioscience Basic Information And Sales Area

Table 90: Coyote Bioscience. Products Portfolio

Table 91: Daan Gene Basic Information And Sales Area

Table 92: Daan Gene. Products Portfolio

Table 93: Orient Gene Basic Information And Sales Area

Table 94: Orient Gene. Products Portfolio

Table 95: Nanjing Synthgene Medical Technology Basic Information And Sales Area

Table 96: Nanjing Synthgene Medical Technology. Products Portfolio

Table 97: Shenzhen Uni-medica Technology Basic Information And Sales Area

Table 98: Shenzhen Uni-medica Technology. Products Portfolio

Table 99: Hybribio Basic Information And Sales Area

Table 100: Hybribio. Products Portfolio

Table 101: BGI Group Basic Information And Sales Area

Table 102: BGI Group. Products Portfolio

Table 103: Global Market Value (USD Million) (2025-2032) By Application

Table 104: Global Market Share (%) By Application (2032)

Table 105: Global Market Value (USD Million) (2025-2032) By Types

Table 106: Global Market Share (%) By Types (2032)

Table 107: Global Market Volume (K) (2025-2032) By Application

Table 108: Global Market Share (%) By Application (2032)

Table 109: Global Market Volume (K) (2025-2032) By Types

Table 110: Global Market Share (%) By Types (2032)

Table 111: Global Novel Coronavirus Nucleic Acid Detection Kit Market Value (USD Million) By Region

Table 112: Global Novel Coronavirus Nucleic Acid Detection Kit Market Share (%) By Region (2025-2032)

Table 113: North America Market Value (USD Million) (2025-2032) By Country

Table 114: North America Market Value (USD Million) (2025-2032) By Application

Table 115: North America Market Value (USD Million) (2025-2032) By Types

Table 116: Europe Market Value (USD Million) (2025-2032) By Country

Table 117: Europe Market Value (USD Million) (2025-2032) By Application

Table 118: Europe Market Value (USD Million) (2025-2032) By Types

Table 119: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 120: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 121: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 122: South America Market Value (USD Million) (2025-2032) By Country

Table 123: South America Market Value (USD Million) (2025-2032) By Application

Table 124: South America Market Value (USD Million) (2025-2032) By Types

Table 125: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 126: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 127: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 128: Global Novel Coronavirus Nucleic Acid Detection Kit Market Volume (K) By Region

Table 129: Global Novel Coronavirus Nucleic Acid Detection Kit Market Share (%) By Region (2025-2032)

Table 130: North America Market Volume (K) (2025-2032) By Country

Table 131: North America Market Volume (K) (2025-2032) By Application

Table 132: North America Market Volume (K) (2025-2032) By Types

Table 133: Europe Market Volume (K) (2025-2032) By Country

Table 134: Europe Market Volume (K) (2025-2032) By Application

Table 135: Europe Market Volume (K) (2025-2032) By Types

Table 136: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 137: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 138: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 139: South America Market Volume (K) (2025-2032) By Country

Table 140: South America Market Volume (K) (2025-2032) By Application

Table 141: South America Market Volume (K) (2025-2032) By Types

Table 142: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 143: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 144: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 145: Research Programs/Design For This Report

Table 146: Key Data Information From Secondary Sources

Table 147: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Novel Coronavirus Nucleic Acid Detection Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	162.00 million
Revenue forecast in 2033	282.54 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; ID SOLUTIONS; altona Diagnostics; GeneProof; Roche Diagnostics; Aurora; 3B BlackBio Biotech India Limited; CerTest Biotec SL; Hologic; Biogerm Medical; GeneoDx Biotech; Liferiver; Mole Bioscience; Bioperfectus; Rendu Biotechnology; Applied Biological; Sansure Biotech; Guangodng Hecin Scientific, Inc.; TransGen Biotech; Coyote Bioscience; Daan Gene; Orient Gene; Nanjing Synthgene Medical Technology; Shenzhen Uni-medica Technology; Hybribio; BGI Group
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Regulatory bottlenecks in emerging markets delay product approvals, creating compliance hurdles for manufacturers aiming to expand geographically.

Opportunities2 items

Collaborations with local diagnostic labs in Asia-Pacific and Latin America offer untapped potential to address testing gaps while reducing supply chain dependencies.

Challenges2 items

Emerging viral variants with altered RNA sequences risk reducing test sensitivity, necessitating frequent re-engineering of detection kits and increasing R&D costs for manufacturers.

Price erosion from competitive pressures and bulk-purchasing mandates by governments threatens profit margins, particularly in saturated markets with mature diagnostic ecosystems.

Market Segmentation

Loading chart…

Novel Coronavirus Nucleic Acid Detection Kit Segmentation Breakdown8 items

Application

Hospital

Clinic

Other

Types

Pharyngeal Swab

Nasal Swab

Other

Regional Insights

Loading chart…

Regional Drivers5 items

North America: High adoption of rapid testing protocols and public-private partnerships.

Europe: Strict regulatory frameworks and EU-funded initiatives to standardize test accuracy.

Asia Pacific: Surging demand in emerging economies and AI-integrated testing solutions.

Latin America: Increased test distribution through international aid and local manufacturing.

Middle East & Africa: Expansion of telehealth infrastructure and pandemic resilience programs.

Competitive Landscape

Abbott: Premium pricing with emphasis on high-throughput PCR systems

Roche Diagnostics: Innovation pipeline targeting multiplex testing

Hologic: Channel strength expansion in hospital diagnostic networks

BGI Group: OEM tie-ups to scale low-cost testing solutions

TransGen Biotech: Regional expansion in Southeast Asia

Sansure Biotech: Cost advantages via localized manufacturing

Key Novel Coronavirus Nucleic Acid Detection Kit Companies26 items

Abbott

ID SOLUTIONS

altona Diagnostics

GeneProof

Roche Diagnostics

Aurora

3B BlackBio Biotech India Limited

CerTest Biotec SL

Hologic

Biogerm Medical

GeneoDx Biotech

Liferiver

Mole Bioscience

Bioperfectus

Rendu Biotechnology

Applied Biological

Sansure Biotech

Guangodng Hecin Scientific, Inc.

TransGen Biotech

Coyote Bioscience

Daan Gene

Orient Gene

Nanjing Synthgene Medical Technology

Shenzhen Uni-medica Technology

Hybribio

BGI Group

Market Ecosystem

Raw material/component suppliers — supply reagents, extraction kits, and PCR consumables for kit production

OEMs/Manufacturers — produce nucleic acid detection kits using validated protocols and standardized formats

Technology providers — license nucleic acid amplification and detection platforms (e.g., PCR, isothermal methods)

System integrators — validate kits for compatibility with laboratory automation and data management systems

Distributors/channel partners — manage logistics, storage, and delivery to healthcare facilities and testing centers

End users — hospitals, diagnostic labs, and public health agencies implementing testing programs

Regulators/standards bodies — oversee CE, FDA, and WHO approvals, ensuring kit performance and safety criteria

Recent Industry Insights

Analyst Overview

Key Insights4 items

The innovation landscape emphasizes rapid RT-PCR advancements, multiplexed testing capabilities, and AI-driven data analytics to enhance detection accuracy and throughput.

The demand–supply balance has improved since 2020, but localized shortages persist due to raw material volatility and geopolitical trade barriers.

Key risk factors include waning public funding, diagnostic fatigue, and potential resistance to nucleic acid tests amid alternative technologies like antigen or serology solutions.

Table of Contents